NanoCinna interests to develop of "Personalized medicine". Personalized medicine is a young but rapidly advancing field of healthcare that is informed by each person's unique clinical, genetic, genomic, and environmental information.  Translational medicine, fueled by the human genome project, has led to open a new field on "Personalized medicine" as "Genomic medicine" which utilized of patient's genomics data to decision of better treatment. 

In order to be thoroughly acquainted with "Genomic medicine", NanoCinna established three research units comprising of Pharmacogenomics, Nanobiotechnology and Bioinformatics. Pharmacogenomics center investigates the genetics profiles of Apoptosis, Angiogenesis, EGFR signaling, Metastasis, Drug resistance and some other pathway and biological networks. Bioinformatics center help us about best statistics and logic analysis of patient genomics data and finally in Nanobiotechnology center we follow the targeting therapy researches such as studying of recombinant mAbs and make a new idea about targeting therapy that we called it "Intelligent anti metastasis engineered proteins (IMEPs)".